Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GLP-DerMap
- Development stage
- Preclinical
- Lead developer
- ArrayPatch
- Modality
- Peptides
- Administration
- Intradermal, Transdermal
01
Overview
GLP-DerMap is a preclinical-stage, polymer-free dissolving microneedle patch designed for the transdermal delivery of glucagon-like peptide-1 (GLP-1) receptor agonists. Developed by ArrayPatch, a spin-out from University College Cork, the platform utilizes a patented technology where the microneedles are composed entirely of the active pharmaceutical ingredient (API) in an amorphous state, allowing for high drug loading without the need for stabilizing polymers. The patch is designed to provide a pain-free, convenient alternative to subcutaneous injections for the treatment of obesity and type 2 diabetes.
- Other names
- GLP-DerMap™
02
Targets
Beyond the preview
Go deeper on GLP-DerMap.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GLP-DerMap.